Natera, Inc.
NTRAHealthcareNASDAQDiagnostics & Research · Last scanned Jul 16, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Natera, Inc. focuses on Diagnostics & Research services and products. Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. With a market capitalization of $39.72B, it sits in large-cap territory. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Market Cap
$39.72B
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-1355.07
EPS (TTM)
$-1.64
EPS (Fwd)
$-0.20
ROE
-15.0%
ROA
-9.1%
Cash
$1.09B
Total Debt
$240.1M
Free CF
$136.9M
52W Change
86.9%
Annual Financials
Cash vs Debt
Natera, Inc. holds $1.09B in cash against $240.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $136.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -15.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $820.2M (2022) to $2.31B (2025), reflecting a 181% increase over the period.
Natera, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing NTRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.